Literature DB >> 15917400

Morphine side effects in beta-arrestin 2 knockout mice.

Kirsten M Raehal1, Julia K L Walker, Laura M Bohn.   

Abstract

Morphine is a potent analgesic, yet, like most opioid narcotics, it exerts unwanted side effects such as constipation and respiratory suppression, thereby limiting its clinical utility. Pharmacological approaches taken to preserve the analgesic properties, while eliminating the unwanted side effects, have met with very limited success. Here, we provide evidence that altering mu opioid receptor regulation may provide a novel approach to discriminate morphine's beneficial and deleterious effects in vivo. We have previously reported that mice lacking the G protein-coupled receptor regulatory protein, beta-arrestin 2, display profoundly altered morphine responses. beta-Arrestin 2 knockout mice have enhanced and prolonged morphine analgesia with very little morphine tolerance. In this report, we examine whether the side effects of morphine treatment are also augmented in this animal model. Surprisingly, the genetic disruption of opioid receptor regulation, while enhancing and prolonging analgesia, dramatically attenuates the respiratory suppression and acute constipation caused by morphine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917400     DOI: 10.1124/jpet.105.087254

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  199 in total

Review 1.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

2.  Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonists.

Authors:  David Winpenny; Mellissa Clark; Darren Cawkill
Journal:  Br J Pharmacol       Date:  2016-03-01       Impact factor: 8.739

Review 3.  G Protein-coupled Receptor Biased Agonism.

Authors:  Sima Y Hodavance; Clarice Gareri; Rachel D Torok; Howard A Rockman
Journal:  J Cardiovasc Pharmacol       Date:  2016-03       Impact factor: 3.105

Review 4.  Functional selectivity of GPCR signaling in animals.

Authors:  Lei Zhou; Laura M Bohn
Journal:  Curr Opin Cell Biol       Date:  2013-12-22       Impact factor: 8.382

Review 5.  Mu opioid receptor regulation and opiate responsiveness.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

6.  Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents.

Authors:  Ahmad A Altarifi; Bethany David; Karan H Muchhala; Bruce E Blough; Hamid Akbarali; S Stevens Negus
Journal:  J Psychopharmacol       Date:  2017-02-01       Impact factor: 4.153

7.  Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation.

Authors:  Chad E Groer; Cullen L Schmid; Alex M Jaeger; Laura M Bohn
Journal:  J Biol Chem       Date:  2011-07-14       Impact factor: 5.157

8.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

9.  A multiplexed fluorescent assay for independent second-messenger systems: decoding GPCR activation in living cells.

Authors:  Paul H Tewson; Anne Marie Quinn; Thomas E Hughes
Journal:  J Biomol Screen       Date:  2013-04-11

10.  Herkinorin analogues with differential beta-arrestin-2 interactions.

Authors:  Kevin Tidgewell; Chad E Groer; Wayne W Harding; Anthony Lozama; Matthew Schmidt; Alfred Marquam; Jessica Hiemstra; John S Partilla; Christina M Dersch; Richard B Rothman; Laura M Bohn; Thomas E Prisinzano
Journal:  J Med Chem       Date:  2008-04-02       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.